Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Immunol ; 41(6): 1652-62, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21469116

ABSTRACT

IL-10-producing CD4(+) type 1 regulatory T (Tr1) cells, defined based on their ability to produce high levels of IL-10 in the absence of IL-4, are major players in the induction and maintenance of peripheral tolerance. Tr1 cells inhibit T-cell responses mainly via cytokine-dependent mechanisms. The cellular and molecular mechanisms underlying the suppression of APC by Tr1 cells are still not completely elucidated. Here, we defined that Tr1 cells specifically lyse myeloid APC through a granzyme B (GZB)- and perforin (PRF)-dependent mechanism that requires HLA class I recognition, CD54/lymphocyte function-associated antigen (LFA)-1 adhesion, and activation via killer cell Ig-like receptors (KIRs) and CD2. Notably, interaction between CD226 on Tr1 cells and their ligands on myeloid cells, leading to Tr1-cell activation, is necessary for defining Tr1-cell target specificity. We also showed that high frequency of GZB-expressing CD4(+) T cells is detected in tolerant patients and correlates with elevated occurrence of IL-10-producing CD4(+) T cells. In conclusion, the modulatory activities of Tr1 cells are not only due to suppressive cytokines but also to specific cell-to-cell interactions that lead to selective killing of myeloid cells and possibly bystander suppression.


Subject(s)
Antigen-Presenting Cells/metabolism , Myeloid Cells/metabolism , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/metabolism , beta-Thalassemia/immunology , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/pathology , Antigens, CD/metabolism , Bystander Effect , Cell Adhesion , Cell Communication , Clone Cells , Cytotoxicity, Immunologic , Granzymes/metabolism , HLA Antigens/metabolism , Humans , Interleukin-10/metabolism , Lymphocyte Function-Associated Antigen-1/metabolism , Myeloid Cells/immunology , Myeloid Cells/pathology , Perforin/metabolism , Receptors, KIR/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/pathology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/pathology
2.
Haematologica ; 95(12): 2134-43, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20713457

ABSTRACT

BACKGROUND: CD4(+) regulatory T cells are a specialized subset of T cells that actively control immune responses. Several experimental protocols have been used to expand natural regulatory T cells and to generate adaptive type 1 regulatory T cells for regulatory T-cell-based therapies. DESIGN AND METHODS: The ability of exogenous recombinant human interleukin-10 to induce alloantigen-specific anergy in T cells was investigated and compared to that of interleukin-10 derived from tolerogenic dendritic cells, in mixed lymphocyte cultures. A detailed characterization of the effector functions of the resulting anergized T cells is reported. RESULTS: Interleukin-10, whether exogenous or derived from tolerogenic dendritic cells, induces a population of alloantigen-specific T cells (interleukin-10-anergized T cells) containing type 1 regulatory T cells, which are anergic and actively suppress alloantigen-specific effector T cells present within the mixed population. Interleukin-10-induced anergy is transforming growth factor-ß independent, and is associated with a decreased frequency of alloantigen-specific cytotoxic T lymphocyte precursors, but interleukin-10-anergized T cells are still responsive to third-party, bacterial, and viral antigens. Tolerogenic dendritic cells are more powerful than exogenous interleukin-10 in generating type 1 regulatory T-cell precursors, and are also effective in the context of HLA-matched donors. CONCLUSIONS: Based on these studies, we have developed an efficient and reproducible in vitro method to generate antigen-specific type 1 regulatory T-cell precursors starting from total peripheral blood cells with minimal cell manipulation and suitable for generating type 1 regulatory T cells for regulatory T-cell-based therapies.


Subject(s)
Cell- and Tissue-Based Therapy/methods , Clonal Anergy/immunology , Isoantigens/immunology , T-Lymphocytes/immunology , Candida albicans/immunology , Cell Proliferation/drug effects , Cells, Cultured , Clonal Anergy/drug effects , Cytomegalovirus/immunology , Gene Expression Profiling , Gene Expression Regulation/drug effects , Humans , Interferon-gamma/metabolism , Interleukin-10/pharmacology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Lymphocyte Culture Test, Mixed , Monocytes/immunology , Monocytes/metabolism , Oligonucleotide Array Sequence Analysis , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , Tetanus Toxoid/immunology , Transforming Growth Factor beta/pharmacology
3.
Haematologica ; 94(10): 1415-26, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19608686

ABSTRACT

BACKGROUND: Thalassemia major can be cured with allogeneic hematopoietic stem cell transplantation. Persistent mixed chimerism develops in around 10% of transplanted thalassemic patients, but the biological mechanisms underlying this phenomenon are poorly understood. DESIGN AND METHODS: The presence of interleukin-10-producing T cells in the peripheral blood of eight patients with persistent mixed chimerism and five with full donor chimerism was investigated. A detailed characterization was then performed, by T-cell cloning, of the effector and regulatory T-cell repertoire of one patient with persistent mixed chimerism, who developed stable split erythroid/lymphoid chimerism after a hematopoietic stem cell transplant from an HLA-matched unrelated donor. RESULTS: Higher levels of interleukin-10 were produced by peripheral blood mononuclear cells from patients with persistent mixed chimerism than by the same cells from patients with complete donor chimerism or normal donors. T-cell clones of both host and donor origin could be isolated from the peripheral blood of one, selected patient with persistent mixed chimerism. Together with effector T-cell clones reactive against host or donor alloantigens, regulatory T-cell clones with a cytokine secretion profile typical of type 1 regulatory cells were identified at high frequencies. Type 1 regulatory cell clones, of both donor and host origin, were able to inhibit the function of effector T cells of either donor or host origin in vitro. CONCLUSIONS: Overall these results suggest that interleukin-10 and type 1 regulatory cells are associated with persistent mixed chimerism and may play an important role in sustaining long-term tolerance in vivo. These data provide new insights into the mechanisms of peripheral tolerance in chimeric patients and support the use of cellular therapy with regulatory T cells following hematopoietic stem cell transplantation.


Subject(s)
Chimerism , Erythroid Cells , Hematopoietic Stem Cell Transplantation , T-Lymphocytes, Regulatory/transplantation , Thalassemia/surgery , Child , Child, Preschool , Erythroid Cells/immunology , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Interleukin-10/immunology , Male , T-Lymphocytes, Regulatory/immunology , Thalassemia/genetics , Thalassemia/immunology , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...